What Is FNDC5? Definition and What Research Reports

Definition

FNDC5 is the abbreviation for fibronectin type III domain-containing protein 5, and it refers both to the human gene and to the protein that gene encodes. The protein is a type I single-pass transmembrane protein: it sits in the cell membrane with a signal peptide, a fibronectin type III domain facing outward, a membrane-spanning segment and a short intracellular tail. Proteolytic processing releases the extracellular fibronectin type III portion into the circulation, and that released fragment was named irisin. Because the cleaved product and its parent protein are studied together, the literature usually writes the pair as FNDC5/irisin. A 2021 review in Endocrine Reviews described the biology of FNDC5 and irisin along with the methodological challenges that have surrounded the field (PMID 33493316).

What Class of Molecule It Is and Where It Comes From

FNDC5 is not a synthetic research peptide in the way that many catalogued sequences are. It is an endogenous protein, meaning the body makes it, with expression described most prominently in skeletal muscle and also detected in other tissues. Irisin, the fragment cleaved from it, is a small glycosylated polypeptide, which is why FNDC5 appears in peptide glossaries at all: the biologically circulating entity studied downstream of FNDC5 is peptide-sized rather than a full-length protein.

The exercise connection

The pathway entered wide circulation because of its link to exercise signalling. The transcriptional coactivator PGC-1α, which rises with muscle activity, drives FNDC5 expression. A 2013 study in Cell Metabolism reported that exercise induced hippocampal BDNF through a PGC-1α/FNDC5 pathway in mice, connecting a muscle-associated gene to a brain growth-factor response (PMID 24120943). That finding is the origin of the frequent shorthand describing FNDC5/irisin as an "exercise-induced" or "exercise-linked" factor.

How the Term Is Used in Peptide Research

In published work, "FNDC5" is used in several distinct senses, and the distinctions matter when reading an abstract:

• The gene. Written in italics in genetics papers; knockout and overexpression models are described as FNDC5 deletion or FNDC5-engineered.
• The membrane protein. The precursor form measured by tissue expression assays.
• The FNDC5/irisin axis. A shorthand for the signalling pathway, used when an experiment cannot cleanly separate precursor from cleaved fragment.
• Recombinant irisin. The laboratory-produced fragment applied to cells or administered to animals in preclinical experiments.

Almost all of the work summarised below was carried out in cultured cells, isolated tissue or rodents. The verified literature cited on this page does not include human dosing trials, so no human administration schedule is described here.

What the Published Literature Reports

Brain and neurons

Neuroscience has been one of the most active areas. A 2019 paper in Nature Medicine reported that exercise-linked FNDC5/irisin rescued synaptic plasticity and memory defects in Alzheimer's disease models (PMID 30617325). In a traumatic brain injury model, researchers reported that FNDC5 prevented oxidative stress and neuronal apoptosis through SIRT3-dependent regulation of mitochondrial quality control (PMID 38802337). A separate 2024 report in Cell Biochemistry and Function described FNDC5/irisin protecting neurons via Caspase3 and Bax pathways (PMID 38269519). A 2025 study used exosomal irisin derived from FNDC5-engineered bone marrow stromal cells and reported improvement in an ischaemic stroke model through inhibition of YAP/EGR1/ACSL4-mediated ferroptosis (PMID 39889877).

Bone

Skeletal work has produced some of the more nuanced findings. A 2024 eLife study reported that deletion of FNDC5/irisin modified murine osteocyte function in a sex-specific manner, meaning male and female animals did not respond identically to loss of the gene (PMID 38661340). A 2025 nanobiotechnology study described FNDC5/irisin-enriched small extracellular vesicles conjugated with a bone-targeting aptamer and reported alleviation of osteoporosis in the model used, with the authors framing the approach as a potential alternative to exercise (PMID 40652239).

Heart and fibrotic tissue

A 2019 paper in Clinical Science reported that FNDC5/irisin inhibited pathological cardiac hypertrophy in the experimental system studied (PMID 30782608). In fibrosis research, the study published in Inflammation reported that FNDC5/irisin attenuated TGF-β-induced fibroblast differentiation via AMPK/Nrf2 signalling and mitochondrial stabilisation in a model of subepithelial fibrosis (PMID 41708900).

Tumour tissue expression

FNDC5/irisin also appears in oncology as a tissue marker rather than as an intervention. A 2022 paper in the International Journal of Molecular Sciences examined the expression of irisin/FNDC5 in breast cancer samples (PMID 35408891), and a 2022 report in In Vivo assessed the significance of irisin (FNDC5) expression in colorectal cancer (PMID 34972713). These were expression and association analyses, not treatment studies.

Terms at a Glance

Measurement and Controversy

Readers encountering FNDC5 for the first time should know that the field carries an unusual amount of methodological debate. The 2021 Endocrine Reviews article was titled around "progress and challenges" precisely because questions about antibody specificity, assay validity and cross-species differences in the gene have shaped how findings are interpreted (PMID 33493316). That review is the standard starting point for anyone reading primary FNDC5 papers, because it sets out which claims rest on well-validated measurement and which rest on contested detection methods.

Adverse Events and Safety Signals: What Studies Report

The verified papers summarised here were preclinical — cell culture, genetic models and rodent experiments — and did not report human adverse-event profiles or tolerability data for an administered product. The closest signal to a safety-relevant observation came from the gene-deletion work: researchers reported that removing FNDC5/irisin altered osteocyte function differently in male and female mice, which indicates that the pathway's role is not uniform across biological sex (PMID 38661340). The oncology expression studies described FNDC5/irisin levels in breast and colorectal tumour tissue without establishing causation in either direction (PMID 35408891, PMID 34972713). No human safety conclusion can be drawn from the sources listed on this page.

Scope of This Entry

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any substance discussed in scientific literature. FNDC5 is a research term describing an endogenous gene and protein, and the findings above were reported in experimental models rather than in approved clinical products.

References

• Progress and Challenges in the Biology of FNDC5 and Irisin (Endocrine Reviews, 2021)
• Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway (Cell Metabolism, 2013)
• Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models (Nature Medicine, 2019)
• FNDC5 prevents oxidative stress and neuronal apoptosis after traumatic brain injury through SIRT3-dependent regulation of mitochondrial quality control (Cell Death & Disease, 2024)
• FNDC5/Irisin protects neurons through Caspase3 and Bax pathways (Cell Biochemistry and Function, 2024)
• Exosomal irisin from FNDC5-engineered BMSCs improves ischemic stroke via inhibiting YAP/EGR1/ACSL4-mediated ferroptosis (Experimental Neurology, 2025)
• Deletion of FNDC5/irisin modifies murine osteocyte function in a sex-specific manner (eLife, 2024)
• FNDC5/irisin-enriched sEVs conjugated with bone-targeting aptamer alleviate osteoporosis: a potential alternative to exercise (Journal of Nanobiotechnology, 2025)
• FNDC5/Irisin inhibits pathological cardiac hypertrophy (Clinical Science, 2019)
• FNDC5/Irisin Attenuates TGF-β-induced Fibroblast Differentiation Via AMPK/Nrf2 Signaling and Mitochondrial Stabilization in Subepithelial Fibrosis (Inflammation, 2026)
• Expression of Irisin/FNDC5 in Breast Cancer (International Journal of Molecular Sciences, 2022)
• Significance of Irisin (FNDC5) Expression in Colorectal Cancer (In Vivo, 2022)